Patents Examined by Ali R. Salimi
  • Polyomavirus diagnostic reagents
    Patent number: 7662912
    Abstract: The present invention relates to HLA-A*02-restricted cellular epitopes within the VP1 polypeptide of human polyomaviruses, which are useful as diagnostic reagents for virus infection. Preferred peptides correspond to amino acids residues 107-116, 108-116 and 44-52 of BKV VP1, and are processed in vivo in natural infection with BKV. Effector T cell populations stimulated by the peptides represent functional CTLs as assessed by cytotoxicity and cytokine production, and are reactive against cells presenting both the BKV peptides above and the JC virus homolog sequences.
    Type: Grant
    Filed: November 19, 2008
    Date of Patent: February 16, 2010
    Assignee: City of Hope
    Inventor: Simon F. Lacey
  • Methods and compositions relating to HPV-associated pre-cancerous and cancerous growths, including CIN
    Patent number: 7659071
    Abstract: The present invention concerns the use of E6 and/or E7 peptides from human papilloma virus (HPV) to evaluate a cell-mediated response in a patient infected with HPV to determine the prognosis for that patient with respect to the development or recurrence of pre-cancerous or cancerous growths, including cervical intraepithelial neoplasia (CIN).
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: February 9, 2010
    Assignee: Board of Regents, the University of Texas System
    Inventors: Jagannadha K. Sastry, Guillermo Tortolero-Luna, Michele Follen
  • Enhancer of anticancer activity in viral therapy and method of preventing or treating cancer
    Patent number: 7655459
    Abstract: The present invention provides a pharmaceutical that safely and effectively enhances the anticancer activity of viral therapy and particularly the antitumor immunity of viral therapy. The present invention also provides a method of preventing or treating cancer that uses this drug. The anticancer activity enhancer according to the present invention contains interleukin as an effective component and is co-administered with a recombinant herpes simplex virus that selectively replicates in cancer cells.
    Type: Grant
    Filed: March 31, 2005
    Date of Patent: February 2, 2010
    Inventor: Tomoki Todo
  • Compositions and methods for vaccinating against HSV-2
    Patent number: 7628993
    Abstract: This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from herpes simplex virus. Also disclosed are therapeutic compositions useful in such a method.
    Type: Grant
    Filed: July 20, 2007
    Date of Patent: December 8, 2009
    Assignees: Vical Incorporated, University of Washington
    Inventors: Adrian Vilalta, Michal Margalith, Lichun Dong, David M. Koelle
  • Circovirus sequences associated with piglet weight loss disease (PWD)
    Patent number: 7625568
    Abstract: The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.
    Type: Grant
    Filed: October 27, 2006
    Date of Patent: December 1, 2009
    Assignee: Wyeth
    Inventors: André Jestin, Emmanuel Albina, Pierre Le Cann, Philippe Blanchard, Evelyne Hutet, Claire Arnauld, Catherine Truong, Dominique Mahe, Roland Cariolet, François Madec
  • MAVS in the prevention and treatment of viral diseases
    Patent number: 7625724
    Abstract: The present invention includes compositions and methods for the identification, characterization and use of a novel anti-viral protein that includes a mitochondrial anti-viral signaling protein.
    Type: Grant
    Filed: August 25, 2006
    Date of Patent: December 1, 2009
    Assignee: Board of Regents, The University of Texas System
    Inventors: Zhijian James Chen, Rashu Seth Bhargava, Lijun Sun, Xiao-Dong Li
  • Circovirus sequences associated with piglet weight loss disease (PWD)
    Patent number: 7622126
    Abstract: The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.
    Type: Grant
    Filed: October 27, 2006
    Date of Patent: November 24, 2009
    Assignee: Wyeth
    Inventors: André Jestin, Emmanuel Albina, Pierre Le Cann, Philippe Blanchard, Evelyne Hutet, Claire Arnauld, Catherine Truong, Dominique Mahe, Roland Cariolet, François Madec
  • Identification of protective antigenic determinants of porcine reproductive and respiratory syndrome virus and uses thereof
    Patent number: 7622254
    Abstract: The invention relates to a polypeptide of a protective antigenic determinant (PAD polypeptide) of porcine reproductive and respiratory syndrome virus (PRRSV) and nucleic acids encoding a PAD polypeptide. The PAD polypeptide and nucleic acids encoding a PAD polypeptide are useful in the development of antibodies directed to PAD, vaccines effective in providing protection against PRRSV infection, and diagnostic assays detecting the presence of PAD antibodies generated by a PAD-specific vaccine. The invention also discloses methods of generating antibodies to PAD, for vaccinating a pig to provide protection from PRRSV infections, a method of preparing the vaccine, a method of treating PRRSV infections in a pig, and a method of detecting antibodies to PAD of PRRSV.
    Type: Grant
    Filed: November 29, 2006
    Date of Patent: November 24, 2009
    Assignee: Iowa State University Research Foundation, Inc.
    Inventors: Delbert Linn Harris, Matthew M. Erdman
  • Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
    Patent number: 7618797
    Abstract: The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, wherein the polynucleotide molecule lacks at least one detectable antigenic epitope of North American PRRS virus. The invention also provides vaccines comprising genetically modified North American PRRS virus, RNA molecules, plasmids and viral vectors comprising the isolated polynucleotide molecules. Also provided are isolated polynucleotide molecules further comprising at least one nucleotide sequence that encodes a detectable heterologous antigenic epitope, and vaccines comprising North American PRRS virus, RNA molecules, plasmids and viral vectors comprising such isolated polynucleotide molecules.
    Type: Grant
    Filed: October 25, 2006
    Date of Patent: November 17, 2009
    Assignee: Pfizer Inc
    Inventors: Jay Gregory Calvert, Michael G. Sheppard, Siao-Kun W. Welch
  • Identifying virally infected and vaccinated organisms
    Patent number: 7611717
    Abstract: This document provides methods and materials related to assessing organisms for the presence or absence of anti-virus antibodies. For example, this document provides methods and materials that can be used to determine whether or not an organism (e.g., a member of a swine species such as a pig) contains anti-PRRS virus antibodies. In other embodiments, this document provides methods and materials that can be used to determine if a particular organism received a vaccine version of a virus, was infected with a naturally-occurring version of the virus, or is naive with respect to the virus.
    Type: Grant
    Filed: June 17, 2005
    Date of Patent: November 3, 2009
    Assignee: Regents of the University of Minnesota
    Inventors: Michael P. Murtaugh, Craig R. Johnson
  • Methods and compositions for vaccination of animals with PRRSV antigens with improved immunogenicity
    Patent number: 7608272
    Abstract: Pigs challenged with hypoglycosylated variants of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) major surface protein GP5 exhibited increased production of PRRSV-neutralizing antibodies relative to the levels of neutralizing antibodies produced by pigs immunized with wild type (wt) or glycosylated GP5. This invention provides for methods of obtaining improved immune responses in pigs to PRRSV, compositions useful for obtaining the improved immune responses as well as isolated polynucleotides that encode hypoglycosylated variants of PRRSV major surface protein GP5.
    Type: Grant
    Filed: August 30, 2006
    Date of Patent: October 27, 2009
    Assignee: Board of Regents of the University of Nebraska
    Inventors: Israrul H. Ansari, Fernando A. Osorio, Asit K. Pattnaik
  • Circovirus sequences associated with piglet weight loss disease (PWD)
    Patent number: 7604808
    Abstract: The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.
    Type: Grant
    Filed: December 28, 2007
    Date of Patent: October 20, 2009
    Assignee: Wyeth
    Inventors: André Jestin, Emmanuel Albina, Pierre Le Cann, Philippe Blanchard, Evelyne Hutet, Claire Arnauld, Catherine Truong, Dominique Mahe, Roland Cariolet, François Madec
  • Prime-boost vaccine for the protection of equines against viral infection
    Patent number: 7601500
    Abstract: It has been found that adequate protection against viral infection in equines can be achieved when vaccination with a live viral vaccine (prime) is followed by vaccination with an inactivated vaccine (boost) for the same virus, wherein the two shots are given no longer than 8 weeks apart. The invention therefore provides a method for vaccination of equines against infection with an equine viral pathogen, wherein an animal is first vaccinated with a (prime) vaccine comprising an attenuated form of the pathogen, followed by a vaccination with a (boost) vaccine comprising the same pathogen in inactivated form, and wherein the boost vaccine is administered no longer than eight weeks after the prime vaccine. The method of the invention is especially useful for vaccination against viral infections such as infections with EIV and/or EHV-1/EHV-4.
    Type: Grant
    Filed: May 2, 2007
    Date of Patent: October 13, 2009
    Assignee: Intervet International B.V.
    Inventor: Saskia van de Zande
  • Prime boost vaccine for the protection of equines against equine influenza
    Patent number: 7601502
    Abstract: The present invention is concerned with vaccinating equines against the equine influenza virus (EIV). It has now been found that adequate protection against equine influenza in equines can be achieved when vaccination with a live equine influenza vaccine (prime) is followed by vaccination with an inactivated influenza vaccine (boost), wherein the two shots are given no longer than 8 weeks apart.
    Type: Grant
    Filed: October 27, 2006
    Date of Patent: October 13, 2009
    Assignee: Intervet International B.V.
    Inventor: Saskia van de Zande
  • T helper cell epitopes
    Patent number: 7572454
    Abstract: The present invention provides T helper cell epitopes and compositions for use in inducing an immune response comprising at least one of these epitopes.
    Type: Grant
    Filed: June 19, 2007
    Date of Patent: August 11, 2009
    Assignees: CSL Limited, The University of Melbourne
    Inventors: David Charles Jackson, Souravi Ghosh, John Walker
  • Promoter gene, recombinant turkey herpesvirus having the novel promoter gene, and poultry vaccine including the recombinant herpes virus of turkey
    Patent number: 7569365
    Abstract: Promoter genes that are derived from Marek's disease virus (MDV). These promoter genes can express two foreign genes when inserted in a recombinant turkey herpesvirus (HVT). A recombinant HVT having said novel promoter gene between two foreign genes. The poultry vaccine consisting of the recombinant turkey herpesvirus described in the present invention.
    Type: Grant
    Filed: March 19, 2008
    Date of Patent: August 4, 2009
    Assignee: Zeon Corporation
    Inventor: Takanori Sato
  • gM-negative EHV-mutants without heterologous elements
    Patent number: 7524506
    Abstract: The present invention relates to the field of animal health and in particular of Equine Herpes Viruses (EHV) wherein the gene encoding the protein gM is absent, and which is free of heterologous elements. Further aspects of the invention relate to pharmaceutical compositions comprising said viruses, uses thereof, and methods for the prophylaxis and treatment of EHV infections. The invention also relates to pharmaceutical compositions comprising the combination of EHV-1 and EHV-4 viruses wherein the gene encoding the protein gM is absent and which is free of heterologous elements.
    Type: Grant
    Filed: October 19, 2006
    Date of Patent: April 28, 2009
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Antonie Neubauer, Christina Ziegler
  • Peptide-based vaccine for influenza
    Patent number: 7514086
    Abstract: A human synthetic peptide-based influenza vaccine for intranasal administration comprises a mixture of flagella containing at least four epitopes of influenza virus reactive with human cells, each expressed individually in Salmonella flagellin, said influenza virus epitopes being selected from the group consisting of: (i) one B-cell hemagglutinin (HA) epitope; (ii) one T-helper hemagglutinin (HA) or nucleo-protein (NP) epitope that can bind to many HLA molecules; and (iii) at least two cytotoxic lymphocyte (CTL) nucleoprotein (NP) or matrix protein (M) epitopes that are restricted to the most prevalent HLA molecules in different human populations.
    Type: Grant
    Filed: February 7, 2007
    Date of Patent: April 7, 2009
    Assignee: Yeda Research and Development, Co. Ltd
    Inventors: Ruth Arnon, Tamar Ben-Yedidia, Raphael Levi
  • Methods and compositions for the detection of cervical disease
    Patent number: 7510838
    Abstract: Methods and compositions for identifying high-grade cervical disease in a patient sample are provided. The methods of the invention comprise detecting overexpression of at least one biomarker in a body sample, wherein the biomarker is selectively overexpressed in high-grade cervical disease. In particular claims, the body sample is a cervical smear or monolayer of cervical cells. The biomarkers of the invention include genes and proteins that are involved in cell cycle regulation, signal transduction, and DNA replication and transcription. In particular claims, the biomarker is an S-phase gene. In some aspects of the invention, overexpression of a biomarker of interest is detected at the protein level using biomarker-specific antibodies or at the nucleic acid level using nucleic acid hybridization techniques. Kits for practicing the methods of the invention are further provided.
    Type: Grant
    Filed: September 14, 2006
    Date of Patent: March 31, 2009
    Assignee: TriPath Imaging, Inc.
    Inventors: Timothy J. Fischer, Douglas P. Malinowski, Adriann J. Taylor, Margaret R. Parker
  • Viral obesity methods and compositions
    Patent number: RE40832
    Abstract: A source of viral induced obesity has been discovered. A virus known as AD-36P adenovirus type 36 has been found to be associated with obesity in both animals and humans. Diagnostic DNA sequences are presented so that DNA based tests for the presence of the obesity associated virus can be conducted.
    Type: Grant
    Filed: October 5, 2007
    Date of Patent: July 7, 2009
    Assignee: Obetech, LLC
    Inventors: Richard L. Atkinson, Nikhil V. Dhurandhar